Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer

CompletedOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Pancreatic Cancer Resectable

Interventions

DRUG

gemcitabine

neoadjuvant therapy for resectable pancreatic cancer using gemcitabine +S1 or gemcitabine + nab-Paxitaxel

All Listed Sponsors

lead

Kochi University

OTHER

NCT06809374 - Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter